AMA applauds FDA, FTC crackdown on sham opioid treatments

| 2 Min Read

CHICAGO — The American Medical Association (AMA) today commended the Food and Drug Administration (FDA) and the Federal Trade Commission for issuing joint warning letters to the marketers and distributors of 12 opioid cessation products for illegally marketing unapproved products with claims about their ability to help in the treatment of opioid addiction and withdrawal. The following statement is attributable to Patrice A. Harris, M.D., chair of the AMA Opioid Task Force.

“This aggressive and timely action will save lives. Our patients with substance use disorder need safe and effective treatment, not sham treatments that fleece them and prey on the stigma surrounding this disorder.

 

Full press release available when you sign in

Sign in to the AMA website to get the full version of this press release. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Figures and large health care icons

Geisinger CMO works to cut friction and lift care

| 7 Min Read
Judge's gavel in movement with a virtual text

Don’t open door to more frivolous medical liability lawsuits

| 5 Min Read
Client at a spa appointment

36 states lack regulatory oversight of med spas

| 6 Min Read
Physician points at tablet

After the survey: Turning physician well-being results into change

| 15 Min Read